NCT02493231

Brief Summary

Many anesthesiologists use the Remifentanil for reducing a surgical pain and stabilizing a vital sign. However, this drug induce postoperative hyperalgesia. Nowadays, many studies report that low-dose Ketamine prevents the opioid-induces hyperalgesia. Nefopam,which is non-opioid analgesic, has similar mechanism with Ketamine. It will be helpful for postoperative pain control, and reduce the needs of opioid.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 2, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 9, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Last Updated

September 2, 2015

Status Verified

August 1, 2015

Enrollment Period

9 months

First QC Date

July 2, 2015

Last Update Submit

August 31, 2015

Conditions

Outcome Measures

Primary Outcomes (2)

  • analgesic requirement

    During 1 hour at PACU

  • duration of analgesic free

    During 1 hour at PACU

Secondary Outcomes (2)

  • analgesic requirement

    During 8 hours after arriving at ward

  • Pain on the VAS scale

    During 1 hour at PACU

Study Arms (3)

Nefopam

ACTIVE COMPARATOR

The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr

Drug: Nefopam

Ketamine

ACTIVE COMPARATOR

It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr

Drug: Ketamine

Saline

PLACEBO COMPARATOR

It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr

Drug: Saline

Interventions

Nefopam
Ketamine
SalineDRUG
Saline

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient who scheduled laparoscopic cholecystectomy under general anesthesia
  • American Society of Anesthesiologist(ASA) class I or II
  • adult patient (age 20 - 65)

You may not qualify if:

  • patient who has liver disease
  • patient who has kidney disease
  • patient who has diabetes mellitus(DM) or heart disease
  • patient who takes opioid or beta-blocker
  • patient who has airway disease
  • patient who has allergy with the drug

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hallym University Kangnam Sacred Heart Hospita

Seoul, South Korea

RECRUITING

MeSH Terms

Conditions

Cholecystitis

Interventions

NefopamKetamineSodium Chloride

Condition Hierarchy (Ancestors)

Gallbladder DiseasesBiliary Tract DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

OxazocinesAzocinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

July 2, 2015

First Posted

July 9, 2015

Study Start

March 1, 2015

Primary Completion

December 1, 2015

Last Updated

September 2, 2015

Record last verified: 2015-08

Locations